{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dry mouth/salivary gland (xerostomia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Dyspnea (shortness of breath)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Fatigue (asthenia, lethargy, malaise)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Glucose, serum-high (hyperglycemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemorrhage - Bronchopulmonary NOS"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infection w/ Grade 3/4 ANC - Skin (cellulitis)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infection w unk ANC - gums (gingivitis)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Mucositis - gums (gingivitis)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neuropathy: sensory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pneumonitis/pulmonary infiltrates"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Potassium, serum-low (hypokalemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Sodium, serum-low (hyponatremia)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"The NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 was utilized.","groups":[{"description":"Patients receive E7389 IV on days 1 and 8 of an every 21-day cycle.","id":"OG000","title":"Treatment (E7389 IV)"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started protocol treatment are included in analysis of toxicity","reportingStatus":"POSTED","timeFrame":"Every 3 weeks while on protocol therapy, up to 3 years.","title":"Participants With a Given Type of AE","type":"SECONDARY","unitOfMeasure":"participants"}